RAM
APLS

Readystate Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Readystate Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
+34,100
New +$735K 0.06% 201
2025
Q4 		– Sell
-241,977
Closed -$5.48M – 392
2025
Q3 		$5.48M Buy
+241,977
New +$5.64M 0.23% 93
2025
Q1 		– Sell
-35,561
Closed -$1.13M – 603
2024
Q4 		$1.13M Buy
+35,561
New +$1.07M 0.03% 384
2024
Q2 		– Sell
-5,438
Closed -$320K – 708
2024
Q1 		$320K Buy
+5,438
New +$347K ﹤0.01% 843

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Readystate Asset Management's APLS Position: Q1 2026 in Review

Readystate Asset Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 34,100 shares worth $1.37M. The stake represents 0.06% of the portfolio and ranks #201 among its holdings. This is a return to the name: Readystate Asset Management previously reported a position in APLS as recently as Q3 2025.

Readystate Asset Management first reported a position in APLS in Q1 2024 and has held it in 4 quarters since. The position peaked at $5.48M in Q3 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Readystate Asset Management held 34,100 shares of Apellis Pharmaceuticals worth $1.37M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Readystate Asset Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.06% of Readystate Asset Management's portfolio in Q1 2026, its #201 holding.
  • Readystate Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • Readystate Asset Management's Apellis Pharmaceuticals position peaked at $5.48M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.